[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]

[IP] abstract on CSII and children

Abstract #:
Abstract Type:  Publish Only 
Abstract Category: Clinical Diabetes: Therapeutics/New Technology 
Abstract Schedule: -,  

Use of Continuous Subcutaneous Insulin Infusion (CSII) Therapy in a Pediatric 
Type 1 Diabetes Mellitus Population 

Objective: The use of continuous subcutaneous insulin infusion(CSII) therapy 
to treat Type 1 diabetes mellitus (DM) has increased steadily in the past few 
years. Use among young children and teenagers with Type 1 DM has also risen 
in the past few years as evidenced by an increase in insulin pump sales and 
the availabilty of insulin pump supplies to this population. Reasons cited by 
pump patients for this increase include increased flexibility that CSII 
therapy frequently allows, a decrease in hypoglycemic unawareness and a 
desire to achieve optimal glycemic control to minimize long-term 
The purpose of the current study is to determine if there is a significant 
difference in glycemic control post CSII initiation in a pediatric 
population. Although subjective data on CSII therapy is readily available in 
health care environments, measureable objective data such as glycemic control 
is limited, especially in the pediatric population.
Research Design: Glycemic control was determined using a Hemoglobin A1c 
(HgbA1c) measurement collected at clinic visits with a normal range of 
4.3-7.0 percent. Hemoglobin A1c means were compared 1 year previous to CSII 
initiation with means 6 months after CSII initiation. Twenty four subjects 
using CSII therapy and meeting study inclusion criteria participated in the 
study out of approximately 50 CSII patients currently receiving care at the 
hospital. Subject ages ranged from 10 to 24 years of age and averaged 16 
years of age. Eleven males and 13 females participated in the study. A paired 
t test was performed to determine if a statistically (P-value < 0.05) and 
clinically significant difference existed between the means.
Results: Results showed that there was not a statistically significant 
difference between pre and post CSII initiation HgbA1c measurements in the 24 
pediatric patients (t-value of -0.26 and P-value of 0.796). In fact, mean 
differences in pre and post CSII HgbA1c measurements were negligible over the 
6 month period.
Conclusion: The outcome of this study, although limited in scope, underscores 
the need for further study in pediatric CSII therapy and the effect on other 
clinical variables such as quality of life and improvement in self-efficacy.

 <A HREF="http://www.diabetes.org/am2000/NumberResults.asp?idAbs=1506">60th 
Scientific Sessions Abstract Display for Abstract Number</A> 
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml